FI78092B - FOERFARANDE FOER FRAMSTAELLNING AV NYA, TERAPEUTISKT ANVAENDBARA 2-BENSYLTIOIMIDAZO / 4,5,1-IJ / KINOLINDERIVAT. - Google Patents

Description

The present invention relates to a process for the preparation of new therapeutically useful 2-benzylthioimidazo [4,5,1-i] quinoline derivatives.

for the preparation of technically useful 2-benzylthioimidazoZ'4,5,1-ijJ-quinoline derivatives of formula I

H1 CXNJ II)

I I

N - = ^ J- S-CH2-Ar 15 wherein the dotted line indicates a possible bond, Ar is a phenyl group optionally mono- or di-substituted with halogen, lower alkyl containing 1 to 6 carbon atoms, or lower alkoxy containing 1 -6 carbon atoms, and 20 is hydrogen, halogen, lower alkyl containing 1 to 6 carbon atoms, or lower alkoxy containing 1 to 6 carbon atoms, and their acid addition salts.

These new compounds are useful in the treatment of ulcers or hypersecretion in mammals.

In our GB patent 203 9218 B we have described e.g. phenylalkylthiopyridines useful in the treatment of ulcers or hypersecretion in mammals. We have now found that modifying the molecule to replace the pyridine group with an imidazoquinoline group yields novel compounds having one or more of the following effects: antiulcer effect, inhibitory effect on secretion or inhibitory effect on H + / K + ATPase .

U.S. Patent 3,200,123 discloses 5,6-di-5-hydroirazazol-7 quinoline derivatives of formula 99 - wherein R may be halogen, mercapto, mercaptoalkyl, hydroxy, trihalomethyl, amino, carboxy, dialkylaminoaminoalkylamino, alkoxy, aryl, heterocycle or heterocycle substituted with various alkyl groups.

These compounds are shown to have anti-inflammatory activity and some of these compounds are reported to have uterotropic activity, hypnotic properties or analgesic properties.

In this specification, the alkyl group is preferably Lower p-alkyl, i.e. alkyl having 1 to 6 carbon atoms, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, n-pentyl or n- hexyl. The alkoxy-25 group is preferably lower alkoxy, where the alkyl moiety is denoted as a lower alkyl group. When the term lower alkyl or lower alkoxy is used in the second group, e.g. aryl-lower alkyl, the lower alkyl or lower alkoxy moiety has 1 to 6 carbon atoms, unless otherwise indicated.

The aralkyl radical is preferably aryl-lower alkyl, e.g. benzyl, phenethyl or phenpropyl.

The acid addition salts of the compounds of formula I * * may be formed from any pharmaceutically acceptable organic or inorganic acid such as chloro-hydrogen, hydrobromic, hydrogen iodine, phosphorus, sulfur, nitrogen, 3,78092 pi, lemon, acetic, formic, fumaric, maleic, tartaric, embonic, malonic, alkylsulfonic, e.g. methanesulfonic, arylsulfonic, e.g. p-toluenesulfonic acid.

The process according to the invention for the preparation of the compounds of the formula I is characterized in that

A) a compound of formula II

Ar-CH2-Hal (II) in which Ar is as defined above and Hal is a halogen atom, in particular chlorine, bromine or iodine, is reacted with a thiol of the formula III or an alkali metal salt thereof R1 L U 1 (HI)

20 I-SH

in which formulas have the same meaning as above, or B) a compound of formula Ha-Ar-CH2-SH (Ha) in which Ar has the same meaning as above or an alkali metal salt thereof is reacted with a halide of formula lila 30 x (lila) 1 ——I — Hai 35 4 78092 wherein is as defined above and Hai is a halogen atom, and optionally isolating the compound of formula I as the free base or as its acid addition salt.

The starting materials of the formulas II and Ha are known compounds or can be prepared by methods known for analogous compounds. The starting materials of the formula III or IIIa are known compounds which are described, for example, in J. Org. Chem. 25 (1960) 10 1138 and 28 (1963) 2581, J. Heterocyclic Chem. 19 (1982) 837, or can be prepared by methods known for analogous compounds. In the process according to the invention, the compounds of the formula I can be isolated as free bases or as their acid addition salts.

The compounds of formula I have an antiulcer effect and / or an inhibitory effect on secretion and are therefore useful in the treatment of ulcers or hypersecretion in mammals.

The antiulcer effect was determined by Senay 20 and Levinen, Proc. Soc. Exp. Biol. Med 124 (1967) 1221-1223, by a test based on stress-induced corrosion.

The inhibitory effect on secretion was determined by the test of H. Shay, D. Sun and H. Gruenstein, Gasteoenterology, 26 (1954), 25 903-913, exemplified by Beattie et al. J. Med. Chem. 20 (1977) 714.

The inhibitory effect of the compounds of formula I on the secretion of their ability to inhibit the highly specific proton transfer system H + / K + 30 ATPase was also tested.

Potential H + / K + ATPase inhibitors are assessed using a technique that measures the accumulation of aminopyrine in isolated rabbit gastric glands. Aminopyrine, a weak base, accumulates in acid-secreting cells. Thus, excitatory stimuli increase aminopyridine uptake and inhibition of acid secretion decreases the response of one or more excretory stimuli depending on the location and effect of the inhibitor. Compounds that reduce the response to dibutyryl-cyclic adenosine monophosphate (DBcAMP) -induced stimulation are believed to act intracellularly, and compounds that reduce the response to both DBcAMP and high potassium ion concentration (K +) act intracellularly in each cell. the site of action of the highly spe-10 specific proton transfer enzyme H + / K + ATPase. The following test procedure was used:

Rabbit gastric glands were isolated from the gastric mucosa of the gastric corpus region by a procedure based on T. Berglindh and K.J. Ohrin, Acta Physiol. Scand.

15 96 (1976) 150-159. Aminopyrine uptake was measured by T. Berglindh, H.F. Hellander and K.J. According to the method described by Ohrin (ibid. 97 (1976) 401-414).

The ability of compounds with an initial concentration of -4 to 10 molar and in some cases lower concentrations to inhibit DBcAMP and correspondingly high K + concentration-stimulated C-aminopyrine uptake in the gastric gland was tested. The results are expressed as the percentage inhibition of the maximal response to excitatory induction by the 25 test compounds. It can be assumed that inhibition of H + / K + ATPase reduces the response to both excitatory stimuli.

6 78092

Table: Results of pharmacological tests

Compound Stress-Induced Inhibition of Excretion Stimulation of Stimulation Pro- e.g. No. (Shay et al.) Cental Inhibition, (Senay & Levine) as a Stimulator_ 5 Dose Percent. cbcamp. K * esto_kons. 1 (T4 tons.lo "1 1 100 83 30 N / A 70 111 2 100 N / A 30 N / A 69 54 3 100 62% 30 N / A 6.7 76 10 4 100 55% 30 N / A 32 .9 83.5 5 100 N / A 30 N / A 53 109 6 100 N / A 30 N / A 40.6 93 7 100 54 30 N / A 40 63 15 N / A = not significantly active

Compounds that show activity in one of the three experiments listed in the table should be considered as antiulcer and / or antihypertensive agents.

The novel compounds of formula I can be used to prepare pharmaceutical compositions comprising solids and liquids. Any suitable carrier known in the art can be used in the preparation of the pharmaceutical composition. Such a carrier for a composition is usually a solid or liquid or a mixture of solid and liquid.

Tablets are prepared by mixing in suitable proportions the active ingredient with a carrier having the necessary compression properties and compressing in the shape and size desired. Powders and tablets suitably contain up to 99%, e.g. 10-80%, preferably 25-75% of active ingredient.

The pharmaceutical composition is preferably in unit dosage form, e.g., as tablets or capsules. In such form, 1 78092, the composition is subdivided into smaller dosage units containing appropriate quantities of the active component. The unit dosage form can be a packet of a composition, e.g., a powder packet. The unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any of these in packaged form. The amount of active ingredient in the dosage unit of the composition may vary or may be adjusted from 10 mg or less to 500 mg or more. depending on the need.

Ulcer barrier compositions containing compounds of formula I are administered orally in the form of either a liquid or solid composition. These compositions may contain one or more antacid ingredients, e.g. aluminum hydroxide, magnesium hydroxide or bismuth carbonate, aluminum glycinate, calcium carbonate, magnesium trisilicate, sodium bicarbonate or aluminum gel, as described in British Patent No. 4.

The following examples illustrate the invention.

Example 1 2-Benzylthio-5,6-dihydro-2H-imidazo [4,5,1-b] quinoline: A solution of 3.5 g of 5,6-dihydro-2-mercapto- [3H7-imidazo] Z. "3,5,1-quinoline in 50 ml of ethanol at reflux, treated with 3.5 ml of benzyl chloride and heated at reflux for three hours. The solution was cooled and crystallization was induced in the solution. The formed crystals were isolated by filtration, washed with ether, dried to give 5.6 g of the title compound as the hydrochloride, mp 168-169 ° C (Found: C 64.2, H 5.4 N 8.7%, C 11 H 10 N 2 .SHCl calculated: C 64.4, H 5 .4, N 8.3%) ·

Example 2 2- (3-Chlorobenzylthio) -5,6-dihydro-Z1H7-imidazo-35 [A, 1,5-i] quinoline

A solution of 3.5 g of 5,6-dihydro-2-mercapto-8,78092H-7'-imidazo [1,5] quinoline in 50 ml of ethanol at reflux was treated with 3.5 ml of m chlorobenzyl chloride and heated at reflux for three hours. The crystals formed during cooling were isolated by filtration, washed with Et 2 O, dried to give 5.3 g of the title compound as the hydrochloride, m.p. 172-175 ° C (Found: C 58.1, H 4.6, N, 8.0%. C 17 H 15 ClN 2 S.HCl calculated: C 57.8, H 4.65, N 8.1%).

Example 3 5,6-Dihydro-2- (4-fluorobenzylthio) -Z% H7-imidazo-CA, 5,1-i-quinoline

A suspension of 5,6-dihydro-2-mercapto-ε4H7-imidazo-A4 → 5,1-i, quinoline in 25 ml of ethanol at reflux was treated with 14.5 g of 4-fluoro-15-benzyl chloride. In 5 ml of ethanol. The solid dissolved rapidly, the mixture was heated at reflux for one hour and cooled. 150 mL of Et 2 O was added and the product was allowed to crystallize. The crystals were removed by filtration, washed with Et 2 O, dried to give 2.5 g (73%) of the title compound as the hydrochloride dihydrate, m.p. 118-120 ° C (Found: 59.5, H 5.2, N 8.3% C 17 H 15 FN 2 S.HCl. 1 / 2H 2 O calculated: C 59.4, H 5.0, N 8.15%).

Example 4 2- (2-Chlorobenzylthio) -5,6-dihydro-Z3H7-imidate-25 SO- [1,5,1-i] quinoline

A suspension of 1.9 g of 5,6-dihydro-2-mercapto-β-4H7-imidazo-ε-5,1-i, quinoline in 25 ml of ethanol at reflux temperature was treated with 1.61 g of chlorobenzyl chloride in ethanol. The suspension became a rapid solution and the mixture was heated at reflux for two hours, filtered, cooled and diluted with 150 ml of ether. The formed crystals were removed by filtration, washed with ether, dried to give 2.6 g (74%) of the title compound as the hydrochloride, m.p. 157-159 ° C (Found: C 58.4, H 4.7, N 8.0%.

C. -H, -ClN-S.HCl calcd: C 58.1 H 4.6, N 8.0%).

1/1!) Δ 9 78092

Example 5 2- (4-Chlorobenzylthio) -5,6-dihydro-η 4 -imidazo-L, 5,1-1,7-quinoline

A suspension of 1.9 g of 5,6-dihydro-2-mercap-5-zO-7H-imidazo-Z-4.5, quinoline in 25 ml of ethanol at reflux was treated with 1.6 g of 4-chlorobenzyl chloride. mlsssa ethanol. The suspended oil dissolved rapidly and the solution was heated at reflux for 1 hour, filtered, cooled and diluted with 75 mL of ether. The formed crystals were removed by filtration, washed with ether, dried to give 1.8 g (50%) of the title compound as the hydrochloride hemihydrate, m.p. 107-108 ° C (Found: C 56.8, H 5.0, N 7.7%.

C17H15ClN2S, HCl.1 / 2H2O calculated: 56.7, H4 * 8'N7'8%) · 15 Example 6 5,6-Dihydro-2- (2-fluorobenzylthio) -Z3H7-imidazo [T 5,1-β-quinoline

A suspension of 1.9 g of 5,6-dihydro-2-mercapto-Z, 4H7-imidazo-Z3,5,13-quinoline in 25 ml of ethanol at reflux temperature was treated with 1.45 g of 2- fluorobenzyl chloride in 5 ml of ethanol and the mixture was heated at reflux for one hour. The resulting solution was filtered and 75 mL of ether was added. The crystals formed on cooling were removed by filtration, washed with ether, dried to give 2.2 g (65%) of the title compound as the hydrochloride, m.p. 167-169 ° C (Found: C 60.9, H, 4.9 N

8.35%. C 17 H 15 FN 2 S.HCl calculated: C 61.0 H 4.5 N 8.4%).

Example 7 2-Benzylthio-Z 3 H 7 -imidazo [4,5,1-i] quinoline 1.88 g of 2-mercapto-2-yl-imidazo [3,5,1-b] quinoline in 20 ml of ethanol at reflux were treated with 1, 2 ml of benzyl chloride, the mixture was heated at reflux for 3.5 hours and cooled. The resulting mixture was diluted with 20 mL of ether and the cream-35 solid was washed with ether, dried to give 2.7 g (86%) of the title compound as the hydrochloride, m.p. 195-198 ° C (Found: C 64.6 H 4.9, N 9.2%. C17H14N2S.HCl Calculated: C 64.85 H 4.8 N 8.9%).

Example 8 2-Benzylthio-5,6-dihydro-Z3-17-imidazo-Z3 / 5,1-quinoline

A solution of 2-chloro-5,6-dihydro-2H-imidazo [1,5,5] quinoline hydrochloride (2.2 g) and benzyl mercaptan (1.4 g) in ethanol (50 ml) , was treated with 5N sodium hydroxide solution (4 ml) and the resulting mixture was heated to reflux for 2 hours. The solution was filtered, acidified with ethereal HCl and cooled to give the title compound as the hydrochloride, m.p. 168-169 ° C. (Found: C 64.2 H 15 5.4, N 8.7%; Cl; LH 10 N 2 S · HCl calculated: C 64.4, H 5.4, N

8.3%).

Example 9 2- (4-Chlorobenzylthio) -5,6-dihydro-2H-imidazole-4,5-1-ylquinoline A solution of 2-chloro-5,6-dihydro-Z3S7-quinoline datsoZT, 5,11-37 quinoline (1.8 g) and 4-chlorobenzyl mercaptan (1.7 g) in ethanol (30 ml) were heated at reflux for 24 hours and cooled. 30 ml of ether were added and the formed crystals were removed from the solution by filtration to give the title compound as the hydrochloride, m.p. 107-108 ° C.

Example 10 5,6-Dihydro-2- (2-fluorobenzylthio) -Z3H7-imidazole. 5,1-1H-Quinoline 2-Chloro-5,6-dihydro-ε-4H7-imidazo [3,5] 1,1-quinoline was reacted with 2-fluorobenzyl mercaptan as described in Example 8. The title compound was obtained as the hydrochloride, m.p. 167-169 ° C.

Claims (8)

A process for the preparation of novel, therapeutically useful 2-benzylthioimidazo [4,5,1-i] [7quinoline derivatives of the formula I "bo I | N-1-S-CH 2 -Ar where dotted line represents an optional bond, Ar is a phenyl group which is optionally mono- or disubstituted with halogen, lower alkyl containing 1-6 carbon atoms or lower alkoxy containing 1-6 carbon atoms, and k is hydrogen, halogen, lower alkyl containing 1-6 carbon atoms, or lower alkoxy containing 1-6 carbon atoms, and acid addition salts thereof, characterized by A) reacting a compound of formula II Ar-CH 2 -Hal (II) wherein Ar is the same as above and Hai is a halogen atom, with a thiol of formula III, or with an alkali metal salt thereof R 30 ly ^ (m) | N - = J-SH 15 7 8092 where R 2 represents the same soin above, or B) reacting a compound of the formula Ha Ar-CH 2 -SH (Ha) wherein Ar represents the same as above, or an alkali metal salt thereof, having a halide of the formula purple R1 (IHa) N -1 - Hai wherein R4 is the same as above and Hai is a halogen atom, and optionally isolating the compound of formula I as a free base or as an acid addition salt thereof. 2. A process according to claim 1, characterized in that 2-benzylthio-5,6-dihydro-β-H7-imidazoZ3, 4,5, 1-quinoline or an acid salt thereof is prepared. 3. A process according to claim 1, characterized in that 2- (3-chlorobenzylthio) -5,6-dihydro-1H7-imidazo / 4,5,1-i} 7quinoline or an acid addition salt thereof is prepared. -; 4. A process according to claim 1, characterized in that 5,6-dihydro-2- (4-fluorophenylmethylthio) -β & H7-imidazo-4,5,1-i] quinoline or an acid addition salt thereof is prepared. 30 5. A process according to claim 1, characterized in that 2- (2-chlorophenylmethylthio) -5,6-dihydro-3,7-imidazo73-5, 1-7-quinoline or an acid addition salt thereof is prepared. Process according to Claim 1, characterized in that 2- (4-chlorophenyl) is prepared.